Mogana Das Murtey | Cancer Cell Biology | Best Researcher Award

Posted on by sciencefather

Dr. Mogana Das Murtey | Cancer Cell Biology | Best Researcher Award

Dr. Mogana Das Murtey , Universiti Sains Malaysia , Malaysia

Dr. Mogana Das Murtey is a Senior University Lecturer at Universiti Sains Malaysia (USM), with extensive expertise in cancer biology, microscopy, and toxicology. She holds a Ph.D. in Molecular and Cellular Biology from USM, where she also earned her Master of Science in Pathology. With more than a decade of teaching experience, Dr. Murtey has contributed significantly to scientific research and education. Her research has focused on cancer prevention, particularly through natural products, and includes groundbreaking studies in toxicology and microscopy techniques. She is a committed mentor and has published extensively in international journals, with multiple awards for her innovative contributions to science. She is an active member of various professional organizations, including the Royal Microscopy Society (UK), and regularly serves as a reviewer for leading journals. Dr. Murtey is dedicated to advancing scientific knowledge in the fields of cancer research and microscopy.

Publication Profile:

Google Scholar

Strengths for the Award:

  1. Extensive Research Experience:

    • Dr. Murtey has significant experience in cancer biology, microscopy, and toxicology, with notable contributions to these fields. His research is regularly published in peer-reviewed journals, such as the Journal of Oncology, Asian Pacific Journal of Cancer Prevention, and Oxidative Medicine and Cellular Longevity.
    • He has contributed as both first and corresponding author in reputable journals, demonstrating leadership and a high level of responsibility in his research endeavors.
    • His work spans multiple cancer types, including breast cancer, cervical cancer, and salivary gland carcinoma, showing both depth and breadth in his research areas.

  2. Innovative Approaches in Cancer Chemoprevention:

    • Dr. Murtey has worked on several groundbreaking studies, particularly in the area of natural product chemoprevention, such as using paddy husk and other plant-based materials to fight cancer. His research could potentially impact public health by offering new, cost-effective cancer treatments or prevention strategies.
    • He has intellectual property (copyright) for novel techniques, including immunogold techniques for scanning electron microscopy, showcasing his contribution to advancing scientific methods.

  3. Teaching and Mentorship:

    • As a Senior University Lecturer, Dr. Murtey has a strong commitment to teaching, having taught a variety of courses in oral biology, histology, and medical sciences, mentoring the next generation of scientists.
    • He has been an academic leader, holding positions like course coordinator and serving on multiple committees within his institution, further highlighting his administrative and leadership qualities.

  4. Recognition and Awards:

    • He has been recognized for his innovative research, including winning gold medals for his work on prostate disease chemoprevention and other health-related innovations.
    • His consistent recognition in prestigious events and competitions reflects the high regard in which his work is held by peers and experts in the field.

  5. Research Grants:

    • Dr. Murtey has secured significant research funding, including bridging and short-term grants from Universiti Sains Malaysia, for projects that involve cutting-edge research on cancer prevention and treatment.

  6. International Collaboration and Publication:

    • His research has international reach, evidenced by publications in global journals and his participation in conferences and symposiums. Furthermore, he serves as a reviewer for multiple respected journals, adding to his credibility and influence within the academic community.

Areas for Improvement:

  1. Increased Focus on Collaborative Research:

    • While Dr. Murtey has a strong individual publication record, more large-scale collaborative projects or multi-disciplinary research could further enhance his impact, particularly in advancing the translation of his findings into clinical or public health applications.

  2. Broader Outreach and Impact:

    • His work, although recognized in academia, could benefit from a stronger outreach strategy aimed at translating his findings into broader societal benefits. This could include partnerships with industry, public health organizations, or policymakers to implement his research at a larger scale.

  3. Grant Diversification:

    • Expanding beyond institutional and national grants to attract more international or industry-backed funding could further solidify his position as a global leader in his field. Additionally, incorporating more collaborative grants with researchers across different fields or industries may provide more extensive funding opportunities.

Education:

Dr. Mogana Das Murtey pursued her academic journey at Universiti Sains Malaysia (USM), where she completed her Ph.D. in Molecular and Cellular Biology (2013-2018). Her research focused on cancer biology and cellular mechanisms, making significant contributions to the understanding of cancer prevention. Prior to her doctoral studies, Dr. Murtey earned a Master of Science in Pathology from USM (2009-2013), where she specialized in understanding diseases at the cellular and molecular levels. She also holds a Bachelor’s degree in Biomedicine (Honours) from Management and Science University (2005-2009), where she first developed her passion for biomedical sciences. Dr. Murtey’s educational background has provided her with a solid foundation in both the theoretical and practical aspects of biomedical research, and she has continually applied her knowledge through teaching, mentoring, and extensive research in her field.

Experience:

Dr. Mogana Das Murtey has over a decade of teaching and research experience in the field of molecular and cellular biology. She is a Senior University Lecturer at Universiti Sains Malaysia (USM), where she has been since 2019. Throughout her career, Dr. Murtey has taught a variety of pathology and oncology-related courses, including Oral Biology, Oral Histology, and Basic Medical Sciences. Her role also includes supervising research projects at both the undergraduate and graduate levels. Before her current position, Dr. Murtey taught part-time at several institutions, including Sultan Abdul Halim Muadzam Shah International Islamic University and Allianze University College of Medical Sciences. In addition to her academic roles, she has been an active researcher, publishing numerous articles in peer-reviewed journals and contributing to groundbreaking work in cancer research and toxicology. Her work has led to several prestigious research grants and collaborations both locally and internationally.

Awards and Honors:

Dr. Mogana Das Murtey has been recognized with multiple awards for her innovative contributions to science. She won the Art Science Competition 2023 organized by the School of Medical Sciences, USM, for her outstanding scientific innovation. She also received a Gold Medal for her research on the chemopreventive agent “Pamentm: New Chemopreventive Agent for Prostate Disease” at the SIRIM Invention, Innovation & Technology Expo 2022. Additionally, Dr. Murtey received the Gold Medal at the Virtual International Research and Innovation Symposium and Exhibition (RISE 2021) at Universiti Tun Hussein Onn Malaysia. Her work has been acknowledged for its impact on advancing cancer research, particularly in cancer prevention through natural products. These awards reflect her commitment to excellence in research and innovation. Dr. Murtey’s achievements underscore her leadership in the academic and research communities.

Research Focus:

Dr. Mogana Das Murtey’s research primarily focuses on cancer biology, toxicology, and microscopy, with a special emphasis on the chemopreventive potential of natural products. Her research aims to identify new ways to prevent and treat various types of cancer, particularly through the use of natural compounds. She has been involved in groundbreaking studies on the pharmacological potentials of paddy waste products, such as husk and straw, in preventing cancer. Dr. Murtey’s work also includes exploring the role of microscopy techniques, such as scanning electron microscopy and immunogold labeling, to study cellular structures in detail. She has also contributed significantly to the understanding of toxicological effects and how certain substances impact cellular function. Her research has been widely published, and she continues to lead projects that explore the intersection of molecular biology, cancer prevention, and environmental science.

Publication Top Notes:

  1. Chemopreventive Potential of Paddy Waste: A Promising Approach Against Benign Prostate Hyperplasia in Spontaneously Hypertensive Rats 🌾💡
  2. Chemoprevention of Natural Products Against Oral Cancer: A Comprehensive Review 🍃🦷
  3. Negative Staining: Forgotten Technique in Microbiology 🧫🔬
  4. Chemopreventive Activity of Two Varieties of Freeze-Dried Coconut Water Against Cervical Cancer Cells, HeLa 🥥🧪
  5. Evaluation of Effect of Honey Sugars Analogue Therapy Against Breast Cancer Induced by 1-Methyl-1-Nitrosourea in In Vivo Breast Cancer Model 🍯🎗️
  6. Effect of Silymarin as an Adjunct Therapy in Combination with Sofosbuvir and Ribavirin in Hepatitis C Patients: A Miniature Clinical Trial 💊🔬
  7. Development of Myocardial Infarction in Rat Model of Diet-Induced Hypercholesterolemia 🐀💔
  8. Gliclazide in Binary and Ternary Systems Improves Physicochemical Properties, Bioactivity, and Antioxidant Activity 💊🌿
  9. Life Science Sample Preparations for Scanning Electron Microscopy 🔬💡
  10. The Phytochemical Analysis and Pharmacological Potentials of Husk and Straw as Paddy Waste Products 🌾🍃

Conclusion:

Dr. Mogana Das Murtey is an exemplary candidate for the “Best Researcher Award” due to his profound contributions to cancer biology, particularly in the areas of chemoprevention and innovative microscopy techniques. His extensive publication record, innovative research methodologies, intellectual property contributions, and recognition from peers and institutions provide compelling evidence of his excellence. While there are areas where increased collaboration and broader outreach could further enhance his career, his consistent track record of success and leadership in both research and teaching positions him as a strong contender for the award.

Weikuan Gu | Cancer Cell Biology | Best Researcher Award

Posted on by sciencefather

Prof. Weikuan Gu | Cancer Cell Biology | Best Researcher Award

Prof. Weikuan Gu , UTHSC , United States

Weikuan Gu is a Professor at the University of Tennessee Health Science Center, specializing in biomedical research with a focus on disease modeling, genetic factors influencing health, and drug efficacy. After earning his MS and Ph.D. from Cornell University, he worked on eye diseases, osteoporosis, and genetics before joining UTHSC in 2002. His contributions in AI applications for biomedical research are noteworthy. He has developed the Principal Law of Lifespan (PLOSP) theory and has been recognized for his leadership in various international collaborative projects. With a significant role in numerous NIH-funded studies, his research continues to push boundaries in understanding disease mechanisms and therapeutics.

Publication Profile: 

Google Scholar

Strengths for the Award:

  1. Extensive Research Experience: Professor Weikuan Gu has over two decades of experience in biomedical research, demonstrating expertise across a wide array of disease models, drug efficacy, and genetic factors influencing health. His work spans a variety of high-impact fields such as ophthalmology, osteoporosis, arthritis, and genomics, showcasing a strong commitment to advancing understanding in multiple medical domains.

  2. Innovative Research Leadership: Professor Gu has been instrumental in leading and contributing to groundbreaking research, including his development of the Principal Law of Lifespan (PLOSP). His ability to innovate, especially in applying AI to biomedical research, positions him at the forefront of cutting-edge science and technology.

  3. Funded Projects & International Collaborations: He has secured substantial funding for his projects, totaling millions of dollars, and has led many high-profile international collaborations. This speaks to the global relevance and potential impact of his work, as well as his ability to manage large-scale research initiatives.

  4. Research Output and Citations: With 175 published scientific papers and multiple accepted articles in prestigious journals such as Cancer Letters and Ecotoxicology and Environmental Safety, his research continues to have a significant impact on the scientific community. His most recent work on AI applications and its implications for public health and disease diagnosis are particularly notable.

  5. Contribution to Education and Training: Professor Gu has played a key role in training future researchers, as evident from his leadership in the Gene Discovery Microarray Core at UTHSC and his involvement in several research education collaborations internationally. His contributions to scientific training are essential for developing the next generation of researchers.

Areas for Improvement:

  1. Broader Public Outreach: While Professor Gu’s research has made significant contributions to the scientific community, there is room to enhance the visibility of his work among broader audiences, including policy makers, healthcare professionals, and the general public. Public engagement with his AI-focused research could improve the real-world application of his findings, especially in public health.

  2. Interdisciplinary Collaboration: Although his collaborations are already diverse, fostering even more interdisciplinary collaborations with experts from areas like data science, engineering, and social sciences could expand the scope of his research, especially in areas like AI and healthcare.

Education:

Dr. Gu completed his MS and Ph.D. from Cornell University, where he specialized in molecular genetics. His academic journey focused on genetic disorders, particularly in disease modeling and understanding complex genetic mechanisms. His research provided foundational insights into eye diseases and osteoporosis, leading to his early work at Loma Linda University and later at the University of Tennessee Health Science Center. His vast academic knowledge enables him to merge genetic research with cutting-edge technologies, including AI applications in biomedical research, paving the way for transformative healthcare solutions.

Experience:

Dr. Weikuan Gu has a rich career that spans over two decades in biomedical research. His early work at Loma Linda University involved osteoporosis and genetic studies in human and mouse models. Since joining the University of Tennessee Health Science Center in 2002, his research expanded to disease modeling, drug efficacy, and the role of genetics in health. He has been a principal investigator and co-investigator in numerous NIH-funded projects, specializing in genetic factors influencing diseases like osteoarthritis, fibrotic diseases, and stroke. Additionally, he is involved in AI-based research, advancing the integration of AI in biomedical research methodologies.

Research Focus:

Dr. Weikuan Gu’s research is centered on understanding disease mechanisms and therapeutic strategies, with a focus on genetic and molecular factors. His work spans glaucoma therapy, fibrotic diseases, and AI in biomedical research. He is the lead on various NIH-funded projects, investigating genetic regulation in conditions like osteoarthritis and stroke. One of his innovative contributions is the Principal Law of Lifespan (PLOSP), a theory aimed at understanding the aging process. His multidisciplinary approach, combining traditional genetic research with modern technologies such as AI, positions him at the forefront of cutting-edge biomedical research.

Publications Top Notes:

  1. “Generating Research Hypotheses to Overcome Key Challenges in the Early Diagnosis of Colorectal Cancer – Future Application of AI” 🧬
  2. “Alarm: Retracted Articles on Cancer Imaging Are Not Only Continuously Cited by Publications but Also Used by ChatGPT to Answer Questions” 💻
  3. “Evaluation of the Potential Value of Artificial Intelligence (AI) in Public Health Using Fluoride Intake as the Example” 🤖

Conclusion:

Professor Weikuan Gu is an exceptionally qualified candidate for the Best Researcher Award. His extensive experience, leadership in innovative research, impressive body of published work, and commitment to advancing both scientific discovery and education make him a standout candidate. While there are opportunities for further enhancing public outreach and expanding interdisciplinary collaborations, his ongoing contributions to AI in biomedicine and genetic research firmly establish him as a leader in his field.

Renate Pichler | Cancer Cell Biology | Best Researcher Award

Posted on by sciencefather

Assoc. Prof. Dr.Renate Pichler | Cancer Cell Biology | Best Researcher Award

Assoc. Prof. Dr. Renate Pichler , Medizinische Universität Innsbruck , Austria

Assoc. Prof. Renate Pichler, MD, PhD, FEBU, is a prominent urologist with a specialization in urological oncology at the Medical University of Innsbruck, Austria. She is the head of the uro-oncological research group, the uro-oncological tumor board, and the special uro-oncological outpatient clinic at the institution. A native of Bolzano, South Tyrol, Pichler holds Italian nationality and has made substantial contributions to cancer research, particularly in the areas of testicular and bladder cancer. She is fluent in German, English, and Italian. With over 170 publications, her research has gained significant attention, earning her an H-index of 32 and over 3,000 citations. She is actively involved in clinical practices, including complex surgeries for penile cancer and bladder cancer management. Pichler’s expertise and leadership make her a respected figure in uro-oncological care and research.

Publication Profile:

Orcid

Strengths for the Award:

Assoc. Prof. Renate Pichler’s exceptional qualifications and impressive career trajectory position her as an outstanding candidate for the Best Researcher Award. As a senior physician specializing in urological oncology at the Medical University of Innsbruck, she demonstrates profound expertise in critical areas such as penile and testicular cancer surgery, uro-oncological endourology, and minimal-invasive surgery. Her leadership roles in multiple uro-oncological research groups and tumor boards further highlight her capacity for both clinical practice and advancing the scientific field. With 172 publications, an H-index of 32, and notable citation impact, she has contributed significantly to urological oncology research. Her ongoing involvement in groundbreaking projects like the “LifeBoost” Cancer Mission lab and liquid biopsy in bladder cancer illustrates her drive for pioneering work.

Areas for Improvement:

Although Prof. Pichler has shown excellence in clinical research, expanding her work in cross-disciplinary collaborations, particularly with emerging technologies such as artificial intelligence in cancer diagnostics, could lead to even more transformative impacts in the field. This would expand her already impressive body of work and provide a broader technological foundation for uro-oncology.

Education:

Assoc. Prof. Renate Pichler’s educational journey started at the Medical University of Innsbruck, where she earned her medical degree (Dr. med. univ.) from 2002 to 2008. She further advanced her expertise by becoming a resident in urology at the Medical University of Innsbruck from 2008 to 2014. During this period, she joined the Urologic Oncology Study Group and contributed to multiple research initiatives. In addition to her medical training, Pichler pursued a Master of Science in Medical Writing (MSc.) at the same institution from 2010 to 2011, enhancing her scientific communication skills. Her education laid the foundation for her career in urological oncology and her commitment to advancing cancer treatment and patient care.

Experience:

Assoc. Prof. Renate Pichler has a distinguished career in urology with a specific focus on uro-oncology. After completing her residency at the Medical University of Innsbruck, she became a senior physician in the Department of Urology, where she now serves as the head of both the uro-oncological research group and the specialized uro-oncological outpatient clinic. Pichler’s clinical expertise includes complex surgeries such as penile cancer operations, radical and modified inguinal lymphadenectomies, as well as endourology and minimal-invasive uro-oncological surgeries. Her leadership in the Comprehensive Cancer Center Innsbruck (CCCI) involves coordinating multidisciplinary tumor boards for optimal treatment plans. Pichler’s vast experience also extends to research in urological oncology, focusing on innovative treatment strategies for bladder and testicular cancer, and overseeing critical studies and clinical trials. Her contributions have firmly established her as a leader in the field.

Awards and Honors:

Assoc. Prof. Renate Pichler has earned multiple prestigious awards throughout her career. Notably, she received the Best Poster Prize at the European Association of Urology (EAU) Congress in both 2011 and 2012, held in Vienna and Paris, respectively. Her exemplary work earned her the 2nd Prize for the Bayer Young Urology Oncology Award at the Annual Conference of the Austrian Society of Urology in 2013. In recognition of her outstanding contributions to the field, Pichler’s research and clinical expertise have also been acknowledged through various grants, including the 2024 “LifeBoost” Cancer Mission Lab grant from the Ludwig Boltzmann Gesellschaft (LBG) and the 2023 Merck KGaA grant for a study on liquid biopsy in bladder cancer. These awards and honors reflect her leadership, innovation, and commitment to improving patient care and advancing uro-oncological research.

Research Focus:

Assoc. Prof. Renate Pichler’s research focuses on advancing uro-oncology, particularly in the treatment of bladder and testicular cancers. Her work explores the molecular mechanisms of cancer, including the regulation of vitamin D metabolism in testicular cancer and the impact of BCG treatment on bladder cancer recurrence. Pichler is dedicated to improving treatment outcomes by investigating biomarkers and therapeutic targets, such as CXCR3 in renal cell carcinoma. She is also deeply involved in enhancing perioperative strategies for bladder cancer surgery and understanding the variations in cancer diagnosis and treatment, including the impact of seasonal factors. As the head of a research group and a multidisciplinary tumor board, her research bridges clinical care with cutting-edge scientific inquiry. Her expertise spans liquid biopsy, photodynamic diagnosis, and targeted therapy, with a strong focus on developing more effective, personalized treatment options for uro-oncological patients.

Publications Top Notes:

  1. Perioperative Outcomes and Trends in Transurethral Resection of Bladder Tumors with Photodynamic Diagnosis 🌐📄
  2. Variation in Follow-Up after Radical Cystectomy for Bladder Cancer 🔬💡
  3. Treating BCG-Induced Cystitis with Combined Chondroitin and Hyaluronic Acid Instillations 💉🩺
  4. Isochromosome 12p Formation Regulates Vitamin D Metabolism in Testicular Cancer 🧬🔬
  5. Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Non-Muscle Invasive Bladder Cancers 💉📊
  6. CXCR3 Expression Is Associated with Advanced Tumor Stage and Grade Influencing Survival in Renal Cell Carcinoma 🧫📈
  7. HUS1 as a Potential Therapeutic Target in Urothelial Cancer 🔬🧪
  8. Seasonal Variations in the Diagnosis of Testicular Germ Cell Tumors 🌞💡
  9. The “COVID-19 Pandemic Gap” and Its Influence on Oncologic Outcomes of Bladder Cancer 🦠💔
  10. Expression of ADAM Proteases in Bladder Cancer Patients with BCG Failure 🔬🚨

Conclusion:

Assoc. Prof. Renate Pichler’s combination of research excellence, clinical expertise, and leadership in urological oncology makes her an ideal candidate for the Best Researcher Award. Her contributions continue to shape the landscape of cancer treatment and diagnosis, ensuring better outcomes for patients worldwide. With a steady record of high-quality publications and successful grants, she exemplifies the dedication and innovation necessary to excel in the medical field.